Developer docs
API playgroundTry for free, no card

Search company profiles

Valar Labs

Full company profile

uuid0000m8z

Namestring
Valar Labs
Legal namestring
Valar Labs
Websiteurl
valarlabs.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Valar Labs is a venture-backed precision oncology company founded in 2021 and headquartered in Palo Alto, California, that builds AI-powered diagnostic tests which analyze routine H&E-stained tumor pathology slides to predict cancer treatment response and stratify risk. Its proprietary Computational Histology Artificial Intelligence (CHAI) platform is trained on more than 500,000 expert pathologist annotations across thousands of patients and operates on local compute infrastructure rather than the cloud. The company ships three commercial products through a branded portfolio architecture: Vesta (genitourinary), comprising Vesta Bladder BCGPredict and Vesta Bladder Risk Stratify for non-muscle invasive bladder cancer, and Vesta Prostate Risk Stratify for metastatic hormone-sensitive prostate cancer; and Vitara (gastrointestinal), anchored by Vitara Pancreas ChemoPredict for first-line chemotherapy selection in advanced pancreatic adenocarcinoma.

Valar Labs monetizes primarily by performing diagnostic tests in its own CLIA-certified laboratory and billing patients and insurers per test, with a Financial Access Program for patients with financial needs, while also generating revenue through professional services partnerships with pharmaceutical companies for biomarker discovery, diagnostic co-development, and automated screening for clinical trial enrollment. Commercial reach is built on a hybrid distribution model combining direct sales to licensed physicians (via the portal.valarlabs.com online portal and a growing urology field sales team) with national laboratory network distribution partnerships, most recently PathNet Lab and Acupath (both December 2025). The customer base spans urologic oncologists treating NMIBC, medical oncologists managing mHSPC and advanced pancreatic cancer, and unnamed leading pharmaceutical companies.

The company is small (11-50 employees, with engineering deliberately capped at seven people who own the full stack from glass slide to clinical report) and has raised approximately $26 million in venture funding, including a $4 million seed round in April 2022 and a $22 million Series A in May 2024 co-led by DCVC and Andreessen Horowitz (a16z) with participation from Pear VC. Validation is anchored in peer-reviewed publications across Journal of Clinical Oncology, European Urology, Journal of Urology, European Urology Oncology, and Cell Reports Medicine, with clinical advisors drawn from Stanford, UTMB, Fred Hutch Cancer Center, Cedars Sinai, and UTSW.

Short descriptiontext

Valar Labs is a Palo Alto-based precision oncology company that uses AI to analyze routine H&E pathology slides and predict cancer treatment response, offering Vesta Bladder, Vesta Prostate, and Vitara Pancreas diagnostics to urologists, oncologists, and pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cancer diagnostics, computational pathology, cancer treatment response prediction, predictive biomarker testing, digital pathology AI
Industry1 code
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Cancer Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Test Sales (CLIA-Certified Laboratory)
TypeManaged Services
Description

Revenue from per-test fees for Vesta Bladder, Vesta Prostate, and Vitara Pancreas tests performed in Valar Labs' own CLIA-certified laboratory. Tests are ordered by licensed physicians, billed to patients and insurers, and Valar Labs offers a Financial Access Program supporting patients with financial needs. Tests are delivered within 2-3 days of sample receipt.

valarlabs.com
2Pharmaceutical R&D Partnerships
TypeProfessional Services
Description

Revenue from partnering with leading pharmaceutical companies to deploy Valar's AI algorithms for advancing R&D programs. Includes biomarker discovery for therapy response prediction, diagnostic development, and automated screening for molecular biomarkers to increase clinical trial enrollment and lower costs.

valarlabs.com
3Laboratory Network Distribution Partnerships
TypeTransaction Fee
Description

Revenue from partnerships with national laboratory networks (PathNet Lab, Acupath) that distribute Vesta AI-powered bladder cancer diagnostics across the United States, expanding clinical access to non-muscle invasive bladder cancer (NMIBC) testing.

clpmag.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Per-test fee for Vesta diagnostic tests (pricing not publicly disclosed)
ModelOther
Notes

Pricing is not publicly disclosed. Financial Access Program available for patients with financial needs. Tests are billed via insurance; Valar Labs submits claims, tracks denials, and manages appeals.

valarlabs.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Vesta
Description

Valar Labs' genitourinary-focused portfolio of AI-powered pathology tests, including Vesta Bladder (Risk Stratify, BCGPredict) and Vesta Prostate Risk Stratify, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.

valarlabs.com
+1 more record
Core offering1 text field

Valar Labs builds AI-powered diagnostic tests (Vesta and Vitara portfolios) that analyze routine H&E-stained tumor pathology slides to predict patient-specific treatment response and stratify risk in bladder, prostate, and pancreatic cancers. Diagnostics are processed in the company's CLIA-certified laboratory and delivered to licensed physicians in 2-3 days. The company also partners with pharmaceutical companies to deploy its AI algorithms for biomarker discovery, diagnostic development, and clinical trial screening automation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Biomarker-present patients have a 2x elevated risk of non-response to BCG compared to biomarker-absent patients (Vesta Bladder BCGPredict).
+6 more records
Product overview1 text field

Valar Labs operates a platform-plus-modules architecture: a single underlying AI platform (CHAI - Computational Histology Artificial Intelligence) powers two distinct branded product portfolios. Vesta is the genitourinary-focused portfolio comprising Vesta Bladder BCGPredict (BCG response prediction for NMIBC), Vesta Bladder Risk Stratify (recurrence/progression risk in NMIBC), and Vesta Prostate Risk Stratify (Favorable vs Unfavorable risk classification for mHSPC triplet therapy selection). Vitara is the gastrointestinal-focused portfolio comprising Vitara Pancreas ChemoPredict (G-Preference vs F-Preference first-line chemotherapy selection for advanced pancreatic adenocarcinoma). All products use the same workflow: receive an existing digitized H&E pathology slide, return a structured AI-generated biomarker report in 2-3 days via Valar Labs' CLIA-certified laboratory and secure online portal, with no additional biopsy required.

Product and service5 records
1Vesta Bladder BCGPredict
CategoryCancer Diagnostic Test (Bladder)
Description

AI pathology diagnostic test for non-muscle invasive bladder cancer (NMIBC) that predicts patient response to intravesical BCG therapy using routine H&E histology slides; biomarker-present patients have a 2x elevated risk of non-response to BCG and demonstrated higher likelihood of success with alternative therapy. Validated in over 1,000 NMIBC patients across an international 12-center cohort. Ordered by licensed physicians.

2Vesta Bladder Risk Stratify
CategoryCancer Diagnostic Test (Bladder)
Description

Prognostic AI test for non-muscle invasive bladder cancer that delivers individualized risk scores for high-grade recurrence and muscle-invasive disease progression. Patients with high recurrence scores have a 2x elevated risk of high-grade recurrence over 24 months; high progression score patients have an almost 4x elevated risk of progression within 3 years. Outperforms existing EAU and AUA stratification frameworks.

3Vesta Prostate Risk Stratify
CategoryCancer Diagnostic Test (Prostate)
Description

AI pathology test for metastatic hormone-sensitive prostate cancer (mHSPC) that classifies patients as Favorable or Unfavorable Risk to predict benefit of triplet therapy (ADT + ARPi + docetaxel) versus doublet therapy. Developed using data from ENZAMET and CHAARTED phase 3 trials in over 1,000 patients; results returned in 2-3 days from a single H&E slide from prostate, lymph node, or bone tissue.

4Vitara Pancreas ChemoPredict
CategoryCancer Diagnostic Test (Pancreatic)
Description

AI pathology test for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that classifies tumors as G-Preference (Gemcitabine/Nab-Paclitaxel) or F-Preference (FOLFIRINOX) based on histologic features, enabling biomarker-matched first-line chemotherapy selection. Developed and validated across over 50 centers including multiple prospective studies; patients with biomarker-aligned regimens showed superior progression-free and overall survival.

5Pharmaceutical R&D AI Partnership Services
CategoryPharmaceutical R&D Services
Description

Partnerships with leading pharmaceutical companies in which Valar Labs deploys its CHAI AI algorithms to advance R&D programs, including biomarker discovery for therapy response prediction, diagnostic development for biomarkers associated with therapy response, and automating molecular biomarker screening to increase clinical trial enrollment and lower costs.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-22
Description

Strategic partnership announced December 22, 2025 to provide AI-powered bladder cancer diagnostics across the United States. The collaboration aims to enhance personalized care and clinical decision-making in non-muscle invasive bladder cancer (NMIBC) by delivering Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict through PathNet's national laboratory network.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-03
Description

Strategic partnership announced December 3, 2025 to deliver Vesta AI-powered diagnostic tests for non-muscle invasive bladder cancer through Acupath's pathology laboratory services.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic partnership announced December 22, 2025 to deliver Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict through PathNet's national laboratory network. Combines Valar Labs' computational pathology capabilities with PathNet's established lab infrastructure to expand adoption of AI-powered bladder cancer diagnostics nationwide for non-muscle invasive bladder cancer (NMIBC) management.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic partnership announced December 3, 2025 to deliver Vesta, an AI-powered diagnostic test for non-muscle invasive bladder cancer. The collaboration leverages Acupath's pathology laboratory services to make Vesta accessible to clinicians managing NMIBC.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Provided data through PanCAN's Know Your Tumor initiative, which was used in Valar Labs' pivotal Journal of Clinical Oncology study validating the Vitara Pancreas ChemoPredict AI diagnostic. The COMPASS clinical trial data was also used in the validation study.

6Leading pharmaceutical companies (unnamed)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Valar Labs partners with leading pharmaceutical companies, deploying AI algorithms to advance R&D programs. Includes biomarker discovery for therapy response, diagnostic development for biomarkers associated with therapy response, and automating molecular biomarker screening to increase trial enrollment and lower costs. Specific pharma partners are not named publicly.

valarlabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Jay Shah, MD (Urologist, Chief of Medical Staff for Stanford Health Care) serves as scientific advisor and user of Vesta, providing clinical testimonials and feedback on Vesta Bladder BCGPredict integration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Stephen B. Williams, MD (Associate Chief Medical Officer, Chief of Urology, Director of Urologic Oncology at UTMB) is a scientific advisor and active user of Vesta Bladder, providing clinical validation and testimonials.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Eric Collisson, MD (oncologist and professor at Fred Hutch Cancer Center) serves as a scientific advisor to Valar Labs and has provided public testimonials about Vesta's clinical impact.

10Cedars Sinai Medical Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Andrew Hendifar, MD (Medical Oncologist and Medical Director of Pancreatic Cancer at Cedars Sinai) serves as a scientific advisor to Valar Labs; lead author of the pivotal Journal of Clinical Oncology study validating Vitara Pancreas ChemoPredict (Hendifar/Knox et al., Feb 2026).

valarlabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Yair Lotan, MD (Chief of Urologic Oncology and Vice Chair of Urology at UTSW) serves as a scientific advisor to Valar Labs; co-author on multiple Vesta Bladder validation studies published in Journal of Urology and European Urology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Artera develops AI-driven prognostic and predictive biomarkers in oncology, with a leading prostate cancer test that personalizes treatment decisions — directly overlapping with Valar Labs' Vesta Prostate Risk Stratify for mHSPC triplet-therapy selection. Both companies build H&E-based AI biomarkers validated in prospective randomized phase 3 trials and commercialize through pathology channels.

TypeDirect peer
Description

PathAI is a leading computational pathology AI company building diagnostic and biomarker products across multiple cancer types, including partnerships with pharma for biomarker development. It overlaps with Valar's CHAI platform in applying deep learning to H&E slides for oncology applications and competes for the same pharma R&D and pathology channel relationships.

TypeDirect peer
Description

Paige builds AI applications for pathology, with FDA-authorized products for prostate cancer detection. Its H&E-based AI diagnostics compete directly with Valar's Vesta Prostate Risk Stratify in the urologic oncology workflow, and Paige offers an established commercial footprint in pathology labs.

TypeDirect peer
Description

Owkin applies AI to pathology and clinical data for biomarker discovery and oncology diagnostics, with a strong biopharma R&D partnership model. It directly mirrors Valar's positioning around AI biomarkers built from histology and deployed across pharma and clinical channels.

5Tempus Labs
TypeBroad incumbent
Description

Tempus is a major precision oncology diagnostics and data company offering molecular profiling, multimodal AI, and clinical decision support across many cancer types. While broader and primarily molecular-based, Tempus is a broad incumbent in oncology AI diagnostics and competes for the same oncologist budgets, pharma partnerships, and guideline-level positioning.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) is an established leader in oncology molecular diagnostics used by oncologists to guide therapy selection. It is a broad incumbent in the personalized cancer treatment space that Valar targets, with deep payer coverage and a large sales force in oncology.

TypeEmerging player
Description

Strata Oncology provides precision oncology diagnostics and a clinical trial screening platform aimed at matching cancer patients to targeted therapies. It overlaps with Valar's pharma R&D offering around biomarker-driven trial enrollment and shares a focus on AI-enabled treatment selection in oncology.

TypeEmerging player
Description

Lunit develops AI-powered pathology and radiology products for cancer detection and treatment response prediction, including biomarkers validated in clinical studies. It is a credible emerging competitor in computational pathology AI that competes with Valar for global oncology diagnostics opportunities.

TypeEmerging player
Description

Ibex builds AI-based pathology diagnostics deployed across multiple cancer types in clinical labs worldwide. It is an emerging player in H&E-based oncology AI that competes with Valar in the pathology channel for diagnostic-grade products.

TypeBroad incumbent
Description

Caris offers molecular profiling and AI-driven precision oncology diagnostics across many tumor types, with a substantial biopharma partnership business. It is a broad incumbent in personalized oncology treatment selection that overlaps with Valar's positioning in AI-guided cancer therapy decisions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valar Labs

AI Cancer Diagnosticsvalarlabs.com

Valar Labs is a Palo Alto-based precision oncology company that uses AI to analyze routine H&E pathology slides and predict cancer treatment response, offering Vesta Bladder, Vesta Prostate, and Vitara Pancreas diagnostics to urologists, oncologists, and pharmaceutical partners.

What Valar Labs does

Valar Labs is a venture-backed precision oncology company founded in 2021 and headquartered in Palo Alto, California, that builds AI-powered diagnostic tests which analyze routine H&E-stained tumor pathology slides to predict cancer treatment response and stratify risk. Its proprietary Computational Histology Artificial Intelligence (CHAI) platform is trained on more than 500,000 expert pathologist annotations across thousands of patients and operates on local compute infrastructure rather than the cloud. The company ships three commercial products through a branded portfolio architecture: Vesta (genitourinary), comprising Vesta Bladder BCGPredict and Vesta Bladder Risk Stratify for non-muscle invasive bladder cancer, and Vesta Prostate Risk Stratify for metastatic hormone-sensitive prostate cancer; and Vitara (gastrointestinal), anchored by Vitara Pancreas ChemoPredict for first-line chemotherapy selection in advanced pancreatic adenocarcinoma.

Valar Labs monetizes primarily by performing diagnostic tests in its own CLIA-certified laboratory and billing patients and insurers per test, with a Financial Access Program for patients with financial needs, while also generating revenue through professional services partnerships with pharmaceutical companies for biomarker discovery, diagnostic co-development, and automated screening for clinical trial enrollment. Commercial reach is built on a hybrid distribution model combining direct sales to licensed physicians (via the portal.valarlabs.com online portal and a growing urology field sales team) with national laboratory network distribution partnerships, most recently PathNet Lab and Acupath (both December 2025). The customer base spans urologic oncologists treating NMIBC, medical oncologists managing mHSPC and advanced pancreatic cancer, and unnamed leading pharmaceutical companies.

The company is small (11-50 employees, with engineering deliberately capped at seven people who own the full stack from glass slide to clinical report) and has raised approximately $26 million in venture funding, including a $4 million seed round in April 2022 and a $22 million Series A in May 2024 co-led by DCVC and Andreessen Horowitz (a16z) with participation from Pear VC. Validation is anchored in peer-reviewed publications across Journal of Clinical Oncology, European Urology, Journal of Urology, European Urology Oncology, and Cell Reports Medicine, with clinical advisors drawn from Stanford, UTMB, Fred Hutch Cancer Center, Cedars Sinai, and UTSW.

Valar Labs firmographics

Firmographics
Name
Valar Labs
Legal name
Valar Labs
Website
https://valarlabs.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Valar Labs is a Palo Alto-based precision oncology company that uses AI to analyze routine H&E pathology slides and predict cancer treatment response, offering Vesta Bladder, Vesta Prostate, and Vitara Pancreas diagnostics to urologists, oncologists, and pharmaceutical partners.
Ownership category
akta.pro rank

Valar Labs industry classification

Industry
Product category
AI Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays

Keywords

  • AI cancer diagnostics
  • Computational pathology
  • Cancer treatment response prediction
  • Predictive biomarker testing
  • Digital pathology AI

Where Valar Labs is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Valar Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Diagnostic Test Sales (CLIA-Certified Laboratory): Revenue from per-test fees for Vesta Bladder, Vesta Prostate, and Vitara Pancreas tests performed in Valar Labs' own CLIA-certified laboratory. Tests are ordered by licensed physicians, billed to patients and insurers, and Valar Labs offers a Financial Access Program supporting patients with financial needs. Tests are delivered within 2-3 days of sample receipt.
  2. Pharmaceutical R&D Partnerships: Revenue from partnering with leading pharmaceutical companies to deploy Valar's AI algorithms for advancing R&D programs. Includes biomarker discovery for therapy response prediction, diagnostic development, and automated screening for molecular biomarkers to increase clinical trial enrollment and lower costs.
  3. Laboratory Network Distribution Partnerships: Revenue from partnerships with national laboratory networks (PathNet Lab, Acupath) that distribute Vesta AI-powered bladder cancer diagnostics across the United States, expanding clinical access to non-muscle invasive bladder cancer (NMIBC) testing.

Pricing tiers

ModelBillingPrice
Other—Per-test fee for Vesta diagnostic tests (pricing not publicly disclosed)

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Valar Labs product offering

Product offering

Core offering

Valar Labs builds AI-powered diagnostic tests (Vesta and Vitara portfolios) that analyze routine H&E-stained tumor pathology slides to predict patient-specific treatment response and stratify risk in bladder, prostate, and pancreatic cancers. Diagnostics are processed in the company's CLIA-certified laboratory and delivered to licensed physicians in 2-3 days. The company also partners with pharmaceutical companies to deploy its AI algorithms for biomarker discovery, diagnostic development, and clinical trial screening automation.

Product overview

Valar Labs operates a platform-plus-modules architecture: a single underlying AI platform (CHAI - Computational Histology Artificial Intelligence) powers two distinct branded product portfolios. Vesta is the genitourinary-focused portfolio comprising Vesta Bladder BCGPredict (BCG response prediction for NMIBC), Vesta Bladder Risk Stratify (recurrence/progression risk in NMIBC), and Vesta Prostate Risk Stratify (Favorable vs Unfavorable risk classification for mHSPC triplet therapy selection). Vitara is the gastrointestinal-focused portfolio comprising Vitara Pancreas ChemoPredict (G-Preference vs F-Preference first-line chemotherapy selection for advanced pancreatic adenocarcinoma). All products use the same workflow: receive an existing digitized H&E pathology slide, return a structured AI-generated biomarker report in 2-3 days via Valar Labs' CLIA-certified laboratory and secure online portal, with no additional biopsy required.

Differentiator

Problem solved

Functional benefit

Brands

  • Vesta: Valar Labs' genitourinary-focused portfolio of AI-powered pathology tests, including Vesta Bladder (Risk Stratify, BCGPredict) and Vesta Prostate Risk Stratify, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.
  • Vitara

Products and services

  • Vesta Bladder BCGPredict AI pathology diagnostic test for non-muscle invasive bladder cancer (NMIBC) that predicts patient response to intravesical BCG therapy using routine H&E histology slides; biomarker-present patients have a 2x elevated risk of non-response to BCG and demonstrated higher likelihood of success with alternative therapy. Validated in over 1,000 NMIBC patients across an international 12-center cohort. Ordered by licensed physicians.
  • Vesta Bladder Risk Stratify Prognostic AI test for non-muscle invasive bladder cancer that delivers individualized risk scores for high-grade recurrence and muscle-invasive disease progression. Patients with high recurrence scores have a 2x elevated risk of high-grade recurrence over 24 months; high progression score patients have an almost 4x elevated risk of progression within 3 years. Outperforms existing EAU and AUA stratification frameworks.
  • Vesta Prostate Risk Stratify AI pathology test for metastatic hormone-sensitive prostate cancer (mHSPC) that classifies patients as Favorable or Unfavorable Risk to predict benefit of triplet therapy (ADT + ARPi + docetaxel) versus doublet therapy. Developed using data from ENZAMET and CHAARTED phase 3 trials in over 1,000 patients; results returned in 2-3 days from a single H&E slide from prostate, lymph node, or bone tissue.
  • Vitara Pancreas ChemoPredict AI pathology test for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) that classifies tumors as G-Preference (Gemcitabine/Nab-Paclitaxel) or F-Preference (FOLFIRINOX) based on histologic features, enabling biomarker-matched first-line chemotherapy selection. Developed and validated across over 50 centers including multiple prospective studies; patients with biomarker-aligned regimens showed superior progression-free and overall survival.
  • Pharmaceutical R&D AI Partnership Services Partnerships with leading pharmaceutical companies in which Valar Labs deploys its CHAI AI algorithms to advance R&D programs, including biomarker discovery for therapy response prediction, diagnostic development for biomarkers associated with therapy response, and automating molecular biomarker screening to increase clinical trial enrollment and lower costs.

Quantifiable outcome

  • Biomarker-present patients have a 2x elevated risk of non-response to BCG compared to biomarker-absent patients (Vesta Bladder BCGPredict).
  • +6 more outcomes

Companies that use Valar Labs

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Valar Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Valar Labs partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • PathNet LabcoreChannel Partner/ Reseller/ Distributor · 22 December 2025Strategic partnership announced December 22, 2025 to provide AI-powered bladder cancer diagnostics across the United States. The collaboration aims to enhance personalized care and clinical decision-making in non-muscle invasive bladder cancer (NMIBC) by delivering Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict through PathNet's national laboratory network.
  • AcupathcoreChannel Partner/ Reseller/ Distributor · 3 December 2025Strategic partnership announced December 3, 2025 to deliver Vesta AI-powered diagnostic tests for non-muscle invasive bladder cancer through Acupath's pathology laboratory services.
  • PathNet LabcoreChannel Partner/ Reseller/ DistributorStrategic partnership announced December 22, 2025 to deliver Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict through PathNet's national laboratory network. Combines Valar Labs' computational pathology capabilities with PathNet's established lab infrastructure to expand adoption of AI-powered bladder cancer diagnostics nationwide for non-muscle invasive bladder cancer (NMIBC) management.
  • AcupathcoreChannel Partner/ Reseller/ DistributorStrategic partnership announced December 3, 2025 to deliver Vesta, an AI-powered diagnostic test for non-muscle invasive bladder cancer. The collaboration leverages Acupath's pathology laboratory services to make Vesta accessible to clinicians managing NMIBC.
  • Pancreatic Cancer Action Network (PanCAN)coreStrategic or Co-development PartnerProvided data through PanCAN's Know Your Tumor initiative, which was used in Valar Labs' pivotal Journal of Clinical Oncology study validating the Vitara Pancreas ChemoPredict AI diagnostic. The COMPASS clinical trial data was also used in the validation study.
  • Leading pharmaceutical companies (unnamed)coreStrategic or Co-development PartnerValar Labs partners with leading pharmaceutical companies, deploying AI algorithms to advance R&D programs. Includes biomarker discovery for therapy response, diagnostic development for biomarkers associated with therapy response, and automating molecular biomarker screening to increase trial enrollment and lower costs. Specific pharma partners are not named publicly.
  • Stanford Health CareminorStrategic or Co-development PartnerJay Shah, MD (Urologist, Chief of Medical Staff for Stanford Health Care) serves as scientific advisor and user of Vesta, providing clinical testimonials and feedback on Vesta Bladder BCGPredict integration.
  • University of Texas Medical Branch (UTMB)minorStrategic or Co-development PartnerStephen B. Williams, MD (Associate Chief Medical Officer, Chief of Urology, Director of Urologic Oncology at UTMB) is a scientific advisor and active user of Vesta Bladder, providing clinical validation and testimonials.
  • Fred Hutch Cancer CenterminorStrategic or Co-development PartnerEric Collisson, MD (oncologist and professor at Fred Hutch Cancer Center) serves as a scientific advisor to Valar Labs and has provided public testimonials about Vesta's clinical impact.
  • Cedars Sinai Medical CenterminorStrategic or Co-development PartnerAndrew Hendifar, MD (Medical Oncologist and Medical Director of Pancreatic Cancer at Cedars Sinai) serves as a scientific advisor to Valar Labs; lead author of the pivotal Journal of Clinical Oncology study validating Vitara Pancreas ChemoPredict (Hendifar/Knox et al., Feb 2026).
  • UT Southwestern (UTSW)minorStrategic or Co-development PartnerYair Lotan, MD (Chief of Urologic Oncology and Vice Chair of Urology at UTSW) serves as a scientific advisor to Valar Labs; co-author on multiple Vesta Bladder validation studies published in Journal of Urology and European Urology.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Valar Labs competitors and assessment

Company assessment

Direct peers

  • Artera (formerly ArteraAI): Artera develops AI-driven prognostic and predictive biomarkers in oncology, with a leading prostate cancer test that personalizes treatment decisions — directly overlapping with Valar Labs' Vesta Prostate Risk Stratify for mHSPC triplet-therapy selection. Both companies build H&E-based AI biomarkers validated in prospective randomized phase 3 trials and commercialize through pathology channels.
  • PathAI: PathAI is a leading computational pathology AI company building diagnostic and biomarker products across multiple cancer types, including partnerships with pharma for biomarker development. It overlaps with Valar's CHAI platform in applying deep learning to H&E slides for oncology applications and competes for the same pharma R&D and pathology channel relationships.
  • Paige.AI: Paige builds AI applications for pathology, with FDA-authorized products for prostate cancer detection. Its H&E-based AI diagnostics compete directly with Valar's Vesta Prostate Risk Stratify in the urologic oncology workflow, and Paige offers an established commercial footprint in pathology labs.
  • Owkin: Owkin applies AI to pathology and clinical data for biomarker discovery and oncology diagnostics, with a strong biopharma R&D partnership model. It directly mirrors Valar's positioning around AI biomarkers built from histology and deployed across pharma and clinical channels.

Broad incumbents

  • Tempus Labs: Tempus is a major precision oncology diagnostics and data company offering molecular profiling, multimodal AI, and clinical decision support across many cancer types. While broader and primarily molecular-based, Tempus is a broad incumbent in oncology AI diagnostics and competes for the same oncologist budgets, pharma partnerships, and guideline-level positioning.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is an established leader in oncology molecular diagnostics used by oncologists to guide therapy selection. It is a broad incumbent in the personalized cancer treatment space that Valar targets, with deep payer coverage and a large sales force in oncology.
  • Caris Life Sciences: Caris offers molecular profiling and AI-driven precision oncology diagnostics across many tumor types, with a substantial biopharma partnership business. It is a broad incumbent in personalized oncology treatment selection that overlaps with Valar's positioning in AI-guided cancer therapy decisions.

Emerging players

  • Strata Oncology: Strata Oncology provides precision oncology diagnostics and a clinical trial screening platform aimed at matching cancer patients to targeted therapies. It overlaps with Valar's pharma R&D offering around biomarker-driven trial enrollment and shares a focus on AI-enabled treatment selection in oncology.
  • Lunit: Lunit develops AI-powered pathology and radiology products for cancer detection and treatment response prediction, including biomarkers validated in clinical studies. It is a credible emerging competitor in computational pathology AI that competes with Valar for global oncology diagnostics opportunities.
  • Ibex Medical Analytics: Ibex builds AI-based pathology diagnostics deployed across multiple cancer types in clinical labs worldwide. It is an emerging player in H&E-based oncology AI that competes with Valar in the pathology channel for diagnostic-grade products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

Valar Labs social profiles

Digital presence

Valar Labs compliance and trust

Trust signal

Compliance3 records

Valar Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valar Labs leadership team

Management profile

Number of profiles

Profiles6 records

Valar Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valar Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valar Labs

What does Valar Labs do?

Valar Labs builds AI-powered diagnostic tests (Vesta and Vitara portfolios) that analyze routine H&E-stained tumor pathology slides to predict patient-specific treatment response and stratify risk in bladder, prostate, and pancreatic cancers. Diagnostics are processed in the company's CLIA-certified laboratory and delivered to licensed physicians in 2-3 days. The company also partners with pharmaceutical companies to deploy its AI algorithms for biomarker discovery, diagnostic development, and clinical trial screening automation.

Is Valar Labs a public or private company?

Valar Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Valar Labs founded?

Valar Labs was founded in 2021. It employs 11 to 50 people.

Where is Valar Labs based?

Valar Labs is headquartered in Palo Alto, United States, in the North America region.

How does Valar Labs make money?

Three revenue lines are on record. Diagnostic Test Sales (CLIA-Certified Laboratory) is the primary driver. The others are pharmaceutical R&D Partnerships and laboratory Network Distribution Partnerships.

Who are Valar Labs's main competitors?

Direct peers on record are Artera (formerly ArteraAI), PathAI, Paige.AI and Owkin. Broad incumbents are Tempus Labs, Foundation Medicine and Caris Life Sciences. Emerging players are Strata Oncology, Lunit and Ibex Medical Analytics.

Does Valar Labs have an API?

No public API is recorded for Valar Labs.

What industry is Valar Labs in?

Valar Labs's product category is AI Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Urology TimesCHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBCA study published in European Urology demonstrates that CHAI biomarkers, developed by Valar Labs, provide superior prognostic risk stratification for high-grade Ta non-muscle-invasive bladder cancer compared to traditional AUA and EAU models. The research indicates these AI-driven biomarkers significantly predict recurrence and progression-free survival independent of standard clinical factors. This validation suggests a potential shift in clinical practice for better identifying patient risk levels.Mpo-magFDA Breakthrough Device Designation Granted for Vesta Bladder Risk Stratify DxValar Labs received FDA Breakthrough Device Designation for its Vesta Bladder Risk Stratify Dx, the first AI-powered digital pathology prognostic test for bladder cancer. The test analyzes standard H&E slides to generate risk assessments, aiming to reduce uncertainty in treatment planning for bladder cancer patients.Medical Device NetworkValar Labs hits US first with breakthrough designation for AI bladder cancer testValar Labs' Vesta Bladder Risk Stratify Dx received FDA breakthrough device designation, becoming the first AI-based digital pathology prognostic test for bladder cancer. The test applies AI to H&E slides to generate risk scores for treatment decisions. Bladder cancer is the tenth leading cause of cancer death in the US.Business Wire BlogValar Labs Receives FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify DxValar Labs received FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx, the first AI-powered digital pathology prognostic test in bladder cancer. The designation expedites review and addresses unmet need in bladder cancer prognosis. The test applies AI to routine H&E slides to generate risk assessments.PancanResearch Spotlight: Latest Advances in Precision MedicineTwo notable advancements in pancreatic cancer treatment were highlighted during Cancer Prevention Month: Novocure received FDA approval for Optune Pax, a wearable device using tumor treating fields combined with chemotherapy for locally advanced pancreatic cancer — the first such approval specifically for this cancer type. Additionally, a study published in the Journal of Clinical Oncology validated an AI-based diagnostic tool developed by Valar Labs that analyzes standard pathology slides to predict tumor response to first-line chemotherapy regimens, offering a personalized treatment approach without invasive testing.STATAs oncologists ponder how to integrate AI-powered cancer tools, products are hitting the marketAI-powered cancer diagnostic and treatment recommendation tools are being developed by companies like Valar Labs and are beginning to hit the market, but oncologists are still working out how to integrate these technologies into clinical practice. These machine learning algorithms can extract insights from tumor images that human pathologists cannot see, potentially helping in situations of clinical equipoise where treatment choices are unclear. Experts say AI could help oncology reach a new level of personalized medicine by guiding clinicians toward the most appropriate treatment for individual patients.BioSpaceValar Labs Publishes Pivotal Study in Journal of Clinical Oncology Validating AI to Predict Chemotherapy Response for Pancreatic Cancer PatientsValar Labs published a pivotal study in the Journal of Clinical Oncology validating their AI diagnostic test, Vitara Pancreas ChemoPredict, which analyzes standard H&E-stained pathology slides to predict advanced pancreatic cancer patient response to first-line chemotherapy regimens. The study used data from PanCAN's Know Your Tumor initiative and the COMPASS clinical trial to demonstrate the AI's ability to help oncologists select between FOLFIRINOX and Gemcitabine/Nab-Paclitaxel chemotherapy options, addressing a critical unmet need in treating one of the deadliest cancers. Valar Labs is now making the Vitara Pancreas ChemoPredict test available under early access to oncologists, marking the company's expansion from genitourinary cancers into gastrointestinal cancers.Business Wire BlogValar Labs Publishes Pivotal Study in Journal of Clinical Oncology Validating AI to Predict Chemotherapy Response for Pancreatic Cancer PatientsValar Labs published a study in the Journal of Clinical Oncology validating an AI-powered biomarker for predicting chemotherapy response in pancreatic cancer patients. The study demonstrates the AI's ability to accurately guide treatment choices, potentially improving patient outcomes.Clinical Lab ProductsValar Labs Partners with PathNet Lab to Expand AI Bladder Cancer DiagnosticsValar Labs has formed a strategic partnership with PathNet Lab to deliver AI-powered bladder cancer diagnostic tools through PathNet's national laboratory network. The collaboration will provide clinicians access to Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict, designed to help urologists and oncologists incorporate AI-driven prognostic and predictive insights into clinical decision-making for non-muscle invasive bladder cancer management. The partnership combines Valar Labs' computational pathology capabilities with PathNet's established laboratory infrastructure to expand adoption of AI-powered diagnostics in bladder cancer care nationwide.Business Wire BlogValar Labs Announces Strategic Partnership with PathNet Lab to Deliver AI-Driven Bladder Cancer Insights NationwideValar Labs announced a strategic partnership with PathNet Lab to deploy its AI-powered Vesta diagnostic portfolio for non-muscle invasive bladder cancer (NMIBC) across PathNet's national clinical network. The collaboration grants PathNet's network of urologists and oncologists access to Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict tools, enabling AI-driven prognostic and predictive insights in clinical decision-making. Both companies stated the partnership aims to advance personalized bladder cancer care and expand adoption of computational pathology diagnostics nationwide.